Self-association and DNA binding properties of the human topoisomerase IIA α2HTH module

Biochimie

Volumn 88, Issue 3-4, 2006, Pages 253-263

  Morant Lhomel, Anne ^a   René, Brigitte ^a   Zargarian, Loussiné ^a   Troalen, Frédéric ^b   Mauffret, Olivier ^a   Fermandjian, Serge ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Dimerization; DNA; DNA binding; Helix turn helix (HTH); Topoisomerase

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); HELIX LOOP HELIX PROTEIN;

ANISOTROPY; ARTICLE; CIRCULAR DICHROISM; CROSS LINKING; CRYSTAL STRUCTURE; DIMERIZATION; DISSOCIATION CONSTANT; DNA BINDING; DNA HELIX; FLUORESCENCE; GEL MOBILITY SHIFT ASSAY; NONHUMAN; PROTEIN CONFORMATION; SOLID STATE; YEAST;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; DIMERIZATION; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELIX-TURN-HELIX MOTIFS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT;

EUKARYOTA;

EID: 33646010297     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2005.08.003     Document Type: Article

References (74)

1. Froelich-Ammon S.J., and Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270 (1995) 21429-21432
2. Hande K.R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta 1400 (1998) 173-184
3. Pommier Y., Pourquier P., Fan Y., and Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400 (1998) 83-105
4. Maxwell A. DNA gyrase as a drug target. Biochem. Soc. Trans. 27 (1999) 48-53
5. Nitiss J.L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr. Opin. Investig. Drugs 3 (2002) 1512-1516
6. Champoux J.J., and Dulbecco R. An activity from mammalian cells that untwists superhelical DNA-a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc. Natl. Acad. Sci. USA 69 (1972) 143-146
7. Wang J.C. Interaction between DNA and an Escherichia coli protein omega. J. Mol. Biol. 55 (1971) 523-533
8. Gellert M., Mizuuchi K., O'Dea M.H., and Nash H.A. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA 73 (1976) 3872-3876
9. Bergerat A., Gadelle D., and Forterre P. Purification of a DNA topoisomerase II from the hyperthermophilic archaeon Sulfolobus shibatae. A thermostable enzyme with both bacterial and eucaryal features. J. Biol. Chem. 269 (1994) 27663-27669
10. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65 (1996) 635-692
11. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
12. Brown P.O., and Cozzarelli N.R. A sign inversion mechanism for enzymatic supercoiling of DNA. Science 206 (1979) 1081-1083
13. Lima C.D., Wang J.C., and Mondragon A. Three-dimensional structure of the 67 K N-terminal fragment of E. coli DNA topoisomerase I. Nature 367 (1994) 138-146
14. Berger J.M., Gamblin S.J., Harrison S.C., and Wang J.C. Structure and mechanism of DNA topoisomerase II. Nature 379 (1996) 225-232
15. Aravind L., Leipe D.D., and Koonin E.V. Toprim-a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res. 26 (1998) 4205-4213
16. Berger J.M., Fass D., Wang J.C., and Harrison S.C. Structural similarities between topoisomerases that cleave one or both DNA strands. Proc. Natl. Acad. Sci. USA 95 (1998) 7876-7881
17. Nichols M.D., DeAngelis K., Keck J.L., and Berger J.M. Structure and function of an archaeal topoisomerase VI subunit with homology to the meiotic recombination factor Spo11. EMBO J. 18 (1999) 6177-6188
18. Brennan R.G., and Matthews B.W. The helix-turn-helix DNA binding motif. J. Biol. Chem. 264 (1989) 1903-1906
19. Harrison S.C., and Aggarwal A.K. DNA recognition by proteins with the helix-turn-helix motif. Annu. Rev. Biochem. 59 (1990) 933-969
20. Schultz S.C., Shields G.C., and Steitz T.A. Crystal structure of a CAP-DNA complex: the DNA is bent by 90 degrees. Science 253 (1991) 1001-1007
21. Clark K.L., Halay E.D., Lai E., and Burley S.K. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364 (1993) 412-420
22. Morais Cabral J.H., Jackson A.P., Smith C.V., Shikotra N., Maxwell A., and Liddington R.C. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388 (1997) 903-906
23. Anderson W.F., Ohlendorf D.H., Takeda Y., and Matthews B.W. Structure of the cro repressor from bacteriophage lambda and its interaction with DNA. Nature 290 (1981) 754-758
24. Pabo C.O., and Lewis M. The operator-binding domain of lambda repressor: structure and DNA recognition. Nature 298 (1982) 443-447
25. Frere V., Sourgen F., Monnot M., Troalen F., and Fermandjian S. A peptide fragment of human DNA topoisomerase II alpha forms a stable coiled-coil structure in solution. J. Biol. Chem. 270 (1995) 17502-17507
26. Lamhasni S., Larsen A.K., Barray M., Monnot M., Delain E., and Fermandjian S. Changes of self-association, secondary structure, and biological activity properties of topoisomerase II under varying salt conditions. Biochemistry 34 (1995) 3632-3639
27. Maucourt K., Agarwal M., René B., and Fermandjian S. Use of Chlamydomonas reinhardtii mutants for anticancer drug screening. Biochem. Pharmacol. 64 (2002) 1125-1131
28. Fossé P., René B., Le Bret M., Paoletti C., and Saucier J.M. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res. 19 (1991) 2861-2868
29. Mauffret O., René B., Convert O., Monnot M., Lescot E., and Fermandjian S. Drug-DNA interactions: spectroscopic and footprinting studies of site and sequence specificity of elliptinium. Biopolymers 31 (1991) 1325-1341
30. Monnot M., Mauffret O., Simon V., Lescot E., Psaume B., Saucier J.M., Charra M., Belehradek Jr. J., and Fermandjian S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. 266 (1991) 1820-1829
31. Amir-Aslani A., Mauffret O., Bittoun P., Sourgen F., Monnot M., Lescot E., and Fermandjian S. Hairpins in a DNA site for topoisomerase II studied by 1H- and 31P-NMR. Nucleic Acids Res. 23 (1995) 3850-3857
32. 31P]-NMR and restrained molecular dynamics of two DNA hairpins from a strong DNA topoisomerase II cleavage site. J. Mol. Biol. 283 (1998) 643-655
33. Frere-Gallois V., Krebs D., Scala D., Troalen F., and Fermandjian S. Peptide fragments of DNA topoisomerase II with helix-forming and coiled-coil-forming properties act as inhibitors of the enzyme. Eur. J. Biochem. 249 (1997) 142-148
34. Christmann-Franck S., Bertrand H.O., Goupil-Lamy A., der Garabedian P.A., Mauffret O., Hoffmann R., and Fermandjian S. Structure-based virtual screening: an application to human topoisomerase II alpha. J. Med. Chem. 47 (2004) 6840-6853
35. Wang J.C. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys. 31 (1998) 107-144
36. Corbett K.D., and Berger J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct. 33 (2004) 95-118
37. Garvie C.W., and Wolberger C. Recognition of specific DNA sequences. Mol. Cell 8 (2001) 937-946
38. Pabo C.O., and Sauer R.T. Protein-DNA recognition. Annu. Rev. Biochem. 53 (1984) 293-321
39. Maxwell A. The molecular basis of quinolone action. J. Antimicrob. Chemother. 30 (1992) 409-414
40. Hsiung Y., Elsea S.H., Osheroff N., and Nitiss J.L. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J. Biol. Chem. 270 (1995) 20359-20364
41. Patel S., Sprung A.U., Keller B.A., Heaton V.J., and Fisher L.M. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol. Pharmacol. 52 (1997) 658-666
42. Everett M.J., and Piddock L.J.V. Resistance to quinolones and fluoroquinolones. In: Kuhlman J., Dalhoff A., and Zeiler H.J. (Eds). Handbook of Experimental Pharmacology: Microbial Resistance to Drugs, Berlin (1998) 259-296
43. Strumberg D., Nitiss J.L., Dong J., Kohn K.W., and Pommier Y. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J. Biol. Chem. 274 (1999) 28246-28255
44. Dong J., Walker J., and Nitiss J.L. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J. Biol. Chem. 275 (2000) 7980-7987
45. Friedman S.M., Lu T., and Drlica K. Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother. 45 (2001) 2378-2380
46. Strumberg D., Nitiss J.L., Dong J., Walker J., Nicklaus M.C., Kohn K.W., Heddle J.G., Maxwell A., Seeber S., and Pommier Y. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action. Antimicrob. Agents Chemother. 46 (2002) 2735-2746
47. Suda N., Ito Y., Imai T., Kikumori T., Kikuchi A., Nishiyama Y., Yoshida S., and Suzuki M. The {alpha}4 residues of human DNA topoisomerase II{alpha} function in enzymatic activity and anticancer drug sensitivity. Nucleic Acids Res. 32 (2004) 1767-1773
48. Critchlow S.E., and Maxwell A. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry 35 (1996) 7387-7393
49. Munoz V., and Serrano L. Development of the multiple sequence approximation within the AGADIR model of alpha-helix formation: comparison with Zimm-Bragg and Lifson-Roig formalisms. Biopolymers 41 (1997) 495-509
50. Garnier J., Gibrat J.F., and Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 266 (1996) 540-553
51. Combet C., Jambon M., Deleage G., and Geourjon C. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics 18 (2002) 213-214
52. Chung T.D., Drake F.H., Tan K.B., Per S.R., Crooke S.T., and Mirabelli C.K. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. USA 86 (1989) 9431-9435
53. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
54. Zhong L., and Johnson Jr. W.C. Environment affects amino acid preference for secondary structure. Proc. Natl. Acad. Sci. USA 89 (1992) 4462-4465
55. Austin C.A., Sng J.H., Patel S., and Fisher L.M. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim. Biophys. Acta 1172 (1993) 283-291
56. Moro S., Beretta G.L., Dal Ben D., Nitiss J., Palumbo M., and Capranico G. Interaction model for anthracycline activity against DNA topoisomerase II. Biochemistry 43 (2004) 7503-7513
57. Tiana G., Shakhnovich B.E., Dokholyan N.V., and Shakhnovich E.I. Imprint of evolution on protein structures. Proc. Natl. Acad. Sci. USA 101 (2004) 2846-2851
58. Armstrong N., de Lencastre A., and Gouaux E. A new protein folding screen: application to the ligand binding domains of a glutamate and kainate receptor and to lysozyme and carbonic anhydrase. Protein Sci. 8 (1999) 1475-1483
59. Lilie H., Schwarz E., and Rudolph R. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol. 9 (1998) 497-501
60. Sourgen F., Maroun R.G., Frere V., Bouziane M., Auclair C., Troalen F., and Fermandjian S. A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Correlated biochemical and spectroscopic results. Eur. J. Biochem. 240 (1996) 765-773
61. Fass D., Bogden C.E., and Berger J.M. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat. Struct. Biol. 6 (1999) 322-326
62. Shuman S. Analysis of topoisomerase-DNA interactions by electrophoretic mobility shift assay. Methods Mol. Biol. 95 (2001) 65-74
63. Carey J. Gel retardation. Methods Enzymol. 208 (1991) 103-117
64. Yang Z., and Champoux J.J. Reconstitution of enzymatic activity by the association of the cap and catalytic domains of human topoisomerase I. J. Biol. Chem. 277 (2002) 30815-30823
65. Heyduk T., and Lee J.C. Application of fluorescence energy transfer and polarization to monitor Escherichia coli cAMP receptor protein and lac promoter interaction. Proc. Natl. Acad. Sci. USA 87 (1990) 1744-1748
66. LeTilly V., and Royer C.A. Fluorescence anisotropy assays implicate protein-protein interactions in regulating trp repressor DNA binding. Biochemistry 32 (1993) 7753-7758
67. Hill J.J., and Royer C.A. Fluorescence approaches to study of protein-nucleic acid complexation. Methods Enzymol. 278 (1997) 390-416
68. Zargarian L., Benleumi M.S., Renisio J.G., Merad H., Maroun R.G., Wieber F., Mauffret O., Porumb H., Troalen F., and Fermandjian S. Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA. J. Biol. Chem. 278 (2003) 19966-19973
69. Liu L.F., and Miller K.G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA 78 (1981) 3487-3491
70. Ferro A.M., and Olivera B.M. Poly(ADP-ribosylation) of DNA topoisomerase I from calf thymus. J. Biol. Chem. 259 (1984) 547-554
71. Nitiss J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta 1400 (1998) 63-81
72. Walker J.V., and Nitiss J.L. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest. 20 (2002) 570-589
73. Hammonds T.R., Foster S.R., and Maxwell A. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis. J. Mol. Biol. 300 (2000) 481-491
74. Strumberg D., Nitiss J.L., Rose A., Nicklaus M.C., and Pommier Y. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. J. Biol. Chem. 274 (1999) 7292-7301